Actinium Pharmaceuticals Announces Filing of Provisional Patent Application Related to Commercial Scale Labeling and Processes for Iomab-B
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced today that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) pertaining to Iomab-B, the Company's Iodine-131 labeled anti-CD45 antibody. This provisional patent application represents the second provisional patent application filing related to Iomab-B following the Company's June 24, 2015 filing for infusion administration of Iomab-B. A provisional patent application is a legal document that...
View full press release